Journal article
A phase II study of the halichondrin B analog eribulin mesylate in gemcitabine refractory advanced pancreatic cancer
Abstract
Background Eribulin mesylate is a halichondrin B analog that inhibits microtubule dynamics. Pre-clinical studies have suggested anti-tumor activity in pancreatic cancer. This phase II study of eribulin in patients with advanced pancreatic cancer previously treated with gemcitabine was conducted by the Princess Margaret Hospital Phase II consortium. Patients and Methods Eligibility criteria included locally advanced or metastatic pancreatic …
Authors
Renouf DJ; Tang PA; Major P; Krzyzanowska MK; Dhesy-Thind B; Goffin JR; Hedley D; Wang L; Doyle L; Moore MJ
Journal
Investigational New Drugs, Vol. 30, No. 3, pp. 1203–1207
Publisher
Springer Nature
Publication Date
June 2012
DOI
10.1007/s10637-011-9673-x
ISSN
0167-6997